Largest insider trades of the week Continue reading...

Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.These investments are inherently volatile in nature. Numerous biotechnology companies have just one or two products delivering revenue, which means any news around new potential treatments has added urgency. That results in bigger price swings. "Pre-revenue" biotech stocks - those with no approved products - are even shakier in nature. These companies are in a race to get a treatment approved before they run out of money for research and trials.Following biotechnology companies isn't like following the rest of the market, either. In many cases, biotech earnings reports aren't a lightning rod for share-price movements. Instead, these stocks tend to ebb and flow on clinical data releases and regulatory approval decisions, which are arguably far more important metrics for gauging biotechnology firms' long-term prospects.So, how are investors supposed to distinguish between the long-term winners and those poised to take an "L"? We suggest taking a page from the analyst community's playbook.Using TipRanks' database, we were able to scan the densely populated industry for the most compelling plays. These biotech stocks not only have earned overwhelmingly bullish support from the Wall Street analysts who cover them, but sky-high upside based on the pros' estimates. Here are seven of Wall Street's best biotech stocks right now, according to the analyst community, which believes each of these picks has triple-digit return potential. SEE ALSO: Pros' Picks: The 15 Best Nasdaq Stocks You Can Buy

Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today the peer-reviewed publication of preclinical data that supports Homology’s HMI-102 investigational gene therapy program for the treatment of adults with phenylketonuria (PKU). HMI-102 is currently being evaluated in the pheNIX Phase 1/2 clinical trial, and the Company plans to provide an update on the trial when selecting the dose for the expansion part, which is currently anticipated in mid-2020.

The CEO of a Cambridge biotech startup promised the company would “deliver in 2020” after announcing a second delay with its first-ever clinical trial.

- Announced Encouraging Initial Clinical Data From the Phase 1/2 pheNIX PKU Gene Therapy Trial and Expects to Select Dose for Randomized, Concurrently Controlled Expansion.

In this article we are going to estimate the intrinsic value of Homology Medicines, Inc. (NASDAQ:FIXX) by taking the...

One of the biggest stories of last week was how Homology Medicines, Inc. (NASDAQ:FIXX) shares plunged 28% in the week...

BEDFORD, Mass., April 29, 2020 -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today upcoming presentations demonstrating the broad.

BioMarin (BMRN) is set to initiate dosing in an early-stage clinical study in the first quarter to evaluate its gene therapy candidate, BMN 307, in phenylketonuria, a rare disease affecting the brain.

Homology Medicines (FIXX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

BEDFORD, Mass., Feb. 20, 2020 -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following investor.

-  Methods Showed Efficient On-Target Gene Integration with No Unintended DNA Modifications - BEDFORD, Mass., May 26, 2020 -- Homology Medicines, Inc. (Nasdaq: FIXX), a.

- Progressed the pheNIX Trial for PKU and Added Clinical Sites, Completed Clinical Supply for Phase 1/2 and Began Manufacturing Pivotal Supply - - Executed Commercial.

If you want a stock market bet that’s 74% likely to lose money, try investing in high-flying stock that sells for 100 times revenue or more Continue reading...

Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today presentations demonstrating that its proprietary adeno-associated virus vectors derived from hematopoietic stem cells (AAVHSCs) crossed the blood-brain-barrier and blood-nerve-barrier in preclinical models. Additionally, in the oral presentation on metachromatic leukodystrophy (MLD), a lysosomal storage disorder caused by mutations in the ARSA gene, Homology’s gene therapy candidate HMI-202 reduced key biomarkers of disease and produced normal levels of human ARSA protein in the murine model of MLD.

Homology Medicines (FIXX) delivered earnings and revenue surprises of 23.61% and 40.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The quarterly results for Homology Medicines, Inc. (NASDAQ:FIXX) were released last week, making it a good time to...

- Molecular Methods Quantified Precision and Efficiency of Nuclease-Free Gene Editing for PKU - - Manufacturing Enhancements Led to Improved Productivity, Quality and.

One of Cambridge’s emerging gene therapy startups has raised $110 million to support the company as it heads toward in-human trials. Generation Bio closed the Series C round this week, bringing in new investors T. Rowe Price, Farallon and Wellington Management, as well as previous backers Atlas Venture, Fidelity and others. The Series C round brings the total money raised by Generation Bio to more than $235 million.